Dr. Gerald Nadal has posted the second part of his article discussing the approval of Ella (ulipristal). The first story discussed Ella's abortifacient properties. In the second installment, Nadal discusses the lack of transparency characteristic of the FDA's handling of the Ella drug application. Go here for his analysis which cites to a filing by the American Association of Obstetricians and Gynecologists (AAPLOG) under the leadership of Dr. Donna Harrison. (Nadal provides a link to the AAPLOG filing.)